Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine

Patent metadata

Field	Value
Publication number	US-10633451-B2
Application number	US-201314376364-A
Country	US
Kind code	B2
Filing date	Jan 24, 2013
Priority date	Feb 3, 2012
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors.host cells, methods for the production of the (bispecific) antibody molecule as well as a kit comprising the (bispecific) antibody molecule of the invention.

First claim

The invention claimed is:

1. A kit comprising
(A) bispecific antibody which comprises
(i) a first binding domain comprising a variable heavy chain (VH) and a variable light chain (VL) which binds an antigen on CD8+ T-cells that does not naturally occur in or on CD8+ T-cells, wherein the antigen is EGFR; and
(ii) a second binding domain comprising a VH and a VL which binds a tumor-specific antigen naturally occurring on the surface of a tumor cell, wherein the antigen is EpCAM;

(B) a nucleic acid encoding EGFR for transducing CD8+ T-cells obtained from a subject to be treated for a cancer, wherein cells of the cancer express EpCAM on their surface; and
(C) instructions for use; wherein the bispecific antibody is to be administered before, simultaneously with, or after administration of the transduced CD8+ T-cells comprising the antigen that does not naturally occur in or on CD8+ T-cells; wherein the CD8+ T-cells were obtained from a subject to be treated for a cancer; wherein cells of the cancer express EpCAM on their surface.

2. The kit of claim 1 , wherein said bispecific antibody is selected from the group consisting of a full antibody, a F(ab)-, Fab′-SH-, Fv-, Fab′-, F(ab′)2-fragment, a chimeric antibody, a CDR-grafted antibody, a fully human antibody, a bivalent antibody-construct, an antibody-fusion protein, a synthetic antibody, a bivalent antibody, a trivalent antibody, a tetravalent antibody, bivalent single chain antibody, a trivalent single chain antibody and a multivalent single chain antibody.

3. The kit of claim 1 , wherein said first domain and/or second binding domain is human and/or humanized.

4. The kit of claim 1 , wherein the transduced CD8+ T-cells further comprises a T-cell receptor that naturally occurs on said T-cells and/or a T-cell receptor that has been genetically introduced into said T-cell.

5. The kit of claim 1 , wherein the bispecific antibody is encoded by a nucleic acid sequence.

6. A bispecific antibody which comprises
(i) a first binding domain comprising a VH and a VL which binds an antigen on CD8+ T-cells that does not naturally occur in or on CD8+ T-cells, wherein the antigen is EGFR; and
(ii) a second binding domain comprising a VH and a VL which binds a tumor-specific antigen naturally occurring on the surface of a tumor cell, wherein the antigen is EpCAM,
wherein said bispecific antibody is to be administered before, simultaneously with or after administration of transduced CD8+ T-cells comprising said antigen which does not naturally occur in or on CD8+ T-cells and wherein said CD8+ T-cells were obtained from a subject to be treated for a cancer, wherein cells of the cancer express EpCAM on their surface.

7. The bispecific antibody of claim 6 , wherein said cancer is of epithelial, endothelial or mesothelial origin, or is a cancer of the blood.

8. The bispecific antibody of claim 6 , wherein said bispecific antibody is selected from the group consisting of a full antibody, a F(ab)-, Fab′-SH-, Fv-, Fab′-, F(ab′)2-fragment, a chimeric antibody, a CDR-grafted antibody, a fully human antibody, a bivalent antibody-construct, an antibody-fusion protein, a synthetic antibody, a bivalent antibody, a trivalent antibody, a tetravalent antibody, bivalent single chain antibody, a trivalent single chain antibody and a multivalent single chain antibody.

9. The bispecific antibody of claim 6 , wherein said first domain and/or second binding domain is human and/or humanized.

10. The bispecific antibody of claim 6 , wherein the transduced CD8+ T-cells further comprises a T-cell receptor that naturally occurs on said T-cells and/or a T-cell receptor that has been genetically introduced into said T-cell.

11. The bispecific antibody of claim 6 , wherein the bispecific antibody is encoded by a nucleic acid sequence.

12. A pharmaceutical composition comprising a bispecific antibody which comprises
(i) a first binding domain comprising a VH and a VL which binds an antigen on CD8+ T-cells that does not naturally occur in or on CD8+ T-cells, wherein the antigen is EGFR; and
(ii) a second binding domain comprising a VH and a VL which binds a tumor-specific antigen naturally occurring on the surface of a tumor cell, wherein the antigen is EpCAM,
which composition is to be administered in combination with transduced CD8+ T-cells comprising said antigen which does not naturally occur in or on CD8+ T-cells, wherein said composition is to be administered before, simultaneously with or after administration of the transduced CD8+ T-cells and wherein said CD8+ T-cells were obtained from a subject to be treated for a cancer, wherein cells of the cancer express EpCAM on their surface.

13. The pharmaceutical composition of claim 12 , wherein said bispecific antibody is selected from the group consisting of a full antibody, a F(ab)-, Fab′-SH-, Fv-, Fab′-, F(ab′)2-fragment, a chimeric antibody, a CDR-grafted antibody, a fully human antibody, a bivalent antibody-construct, an antibody-fusion protein, a synthetic antibody, a bivalent antibody, a trivalent antibody, a tetravalent antibody, bivalent single chain antibody, a trivalent single chain antibody and a multivalent single chain antibody.

14. The pharmaceutical composition of claim 12 , wherein said first domain and/or second binding domain is human and/or humanized.

15. The pharmaceutical composition of claim 12 , wherein the transduced CD8+ T-cells further comprises a T-cell receptor that naturally occurs on said T-cells and/or a T-cell receptor that has been genetically introduced into said T-cell.

16. The pharmaceutical composition of claim 12 , wherein the bispecific antibody is encoded by a nucleic acid sequence.

Assignees

• Hoffmann La Roche
• Ludwig Maximillians Univ Muenchen

Inventors

• Bourquin Carole
• Castoldi Raffaella
• Endres Stefan
• Klein Christian
• Kobold Sebastian
• Niederfellner Gerhard
• Sustmann Claudio

Classifications

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• Y02P20/582

  Recycling of unreacted starting or intermediate materials · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/30 Primary

  from tumour cells · CPC title